PCF & The VA: Shepherding Extraordinary Care

Every year, 12,000 more veterans are diagnosed with prostate cancer. The Prostate Cancer Foundation (PCF) and the Department of Veterans Affairs (VA) are partnering to prevent, screen and promote research to speed the development of treatments and cures for prostate cancer among veterans.

As part of the PCF/VA collaboration, PCF funded researcher, Dr. Bruce Montgomery, performed deep genetic sequencing of patient Christopher Seelye’s cancer; the resulting drug regimen created an extraordinary response for his metastatic disease… taking him from a PSA of 200 to 1, and moving his metastatic scans to clear.

Watch the video below to learn more about the PCF/VA partnership and Christopher Seelye’s extraordinary response to treatment.

Click here to learn more about the partnership between PCF and the VA.

Terms to know from this article:


prostate-specific antigen (PSA): A substance produced by the prostate that may be found in an increased amount in the blood of men who have prostate cancer, benign prostatic hyperplasia, or infection or inflammation of the prostate.